NH TherAguix and Jean PERRIN Cancer Centre in Clermont-Ferrand
announce the completion of phase I recruitment and the entry into Phase II for the Nano-GBM phase I/II trial in glioblastoma with the two first patients included.
NH TherAguix and Jean PERRIN Cancer Centre in Clermont-Ferrand
announce the completion of phase I recruitment and the entry into Phase II for the Nano-GBM phase I/II trial in glioblastoma with the two first patients included.
NH TherAguix announced the appointment of Vincent Carrère as Chief Executive Officer (CEO).
NH TherAguix is happy to announce that 4 communications related to AGuIX will be provided during the American Association for Physicists in Medicine annual meeting in Houston, Texas, USA by our US collaborators
NH TherAguix, a French clinical biotech specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, announces today the arrival of Aurélien Meyzaud as Head of Intellectual Property and Business Intelligence from January 2.
NH TherAguix is pleased and proud to announce that Mr Paul Rocchi successfully defended his thesis, as the first CIFRE PhD student of the company – Oct. 06, 2022.
NH TherAguix (“NHT”), announces today the arrival of Dr. Olivier de Beaumont as Chief Medical Officer from September 2022. – Sept. 09, 2022.
NH TherAguix et le Centre de Lutte Contre le Cancer Jean PERRIN de Clermont-Ferrand annoncent le recrutement du premier patient de l’étude de phase I/II Nano-GBM ciblant les glioblastomes nouvellement diagnostiqués, étude promue par le Centre Jean PERRIN et dirigée par le Dr Julian Biau, oncologue-radiothérapeute – Grenoble et Clermont-Ferrand (France) – May 13, 2022.
Meylan (France) and Boston (US), October 1st, 2021 – NH TherAguix announces the enrolment of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis and NANOSMART Phase Ib/II targeting pancreatic cancer and cancerous lung lesions.
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients – Grenoble (France), May 31, 2021 – 11:00 pm (CET)
NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance – Grenoble/Lyon/Paris (France) – 11 April 2019
Sanofi and Lyon start-up NH TherAguix team up to produce AGuIX®, an innovative nanoparticle in oncology – Paris (France) – February, 18, 2019